Complete Story
 

ROZLYTREK™ (entrectinib) is now FDA approved

ROZLYTREK™ (entrectinib)
is now FDA approved
for the treatment of adult patients with metastatic non-small cell lung
cancer (NSCLC) whose tumors are
ROS1-positive.
https://www.rozlytrek.com/hcp.html
 ----------------------------
 
Effective July 1, 2019 the permanent J-code for Herceptin HYLECTA is J9356.  https://www.genentech-access.com/hcp/brands/herceptinhylecta.html
 
-----------------------------
On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval for POLIVY™ (polatuzumab vedotin-piiq) in combination with bendamustine and rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least 2 prior therapies. https://www.polivy.com/hcp.html
 
-----------
 
What should be in Patient Assistance section:
Logo is attached. These two links should be included.

Printer-Friendly Version